Overview

A Study of Repeat-Dose Subcutaneous Darbepoetin Alfa in Subjects With Congestive Heart Failure and Anemia, and a Single Dose in Healthy Age- and Sex-Matched Control Subjects

Status:
Completed

Trial end date:
2004-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the single dose pharmacokinetics (PK) of subcutaneous (SC) darbepoetin alfa in subjects with congestive heart failure (CHF) and anemia.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Amgen

Treatments:

Darbepoetin alfa